RE:RE:Final clinical results of N-803 BCG Unresponsive NMIBC Trialenriquesuave wrote: Same results as before. Very good, but it's also a combination therapy 2 drugs will always work synergistically and give added efficacy. TLD-1433 single agent should give us results very close to those IMO after full trial results, but we will be 1 single treatment vs 15-21 instillations. All IMHO
If we achieve similar efficacy with only two required treatments vs 15+, that'll be a no-brainer. Also, the BCG shortage has precluded its use in many urologic practices & a restricted supply will generally drive prices higher. Imo, docs will continue to look for other options that are more feasible/practical for both their patients & busy practices. If FDA approved, TLT's more simplified single-agent/two-treatment option should provide stiff competition against any immunotherapeutic or chemotherapeutic combo therapy.
And it's not a far stretch to think that an additional treatment of our ACT (if needed) or if used in combination with chemo or an immunotherapeutic could very well surpass any other combo option.
Another area that warrants further study is figuring out the best method to maximize delivery of an intravesical drug. Imo, the primary efficacy-limiting factor with our ACT is most likely attributed to less-than-maximal drug/light absorption...not the mechanism of its cancer cell destruction. I expect our ACT will eventually reach even higher heights once this limiting step in our intravesical treatment protocol is further perfected. We already learned that maximizing bladder volume (increasing pressure) logically increases drug absorption & hence efficacy. All imo. GLTA.